A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced or Metastatic Her-2-Positive Breast Cancer.

Trial Profile

A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced or Metastatic Her-2-Positive Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs BMS 754807; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 12 Jul 2012 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
    • 04 Mar 2012 EudraCT reports actual initiation date as Apr 2010; additional trial centre identified and inclusion, exclusion criteria amended.
    • 03 Mar 2012 Planned End Date changed from 1 Mar 2012 to 1 Apr 2013 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top